IPHA
Innate Pharma S.A.
NASDAQ · Healthcare · Biotechnology · FR
$2.08
−1.42%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 15.4M | 2.8M | 12.6M | 51.9M | 57.7M |
| Cost of Revenue | 20.5M | — | 52.0M | 56.0M | 51.7M |
| Gross Profit | 15.4M | 2.8M | 12.6M | 5.6M | 6.0M |
| Operating Expenses | |||||
| R&D Expense | 95.4M | 43.6M | 52.0M | 56.0M | 51.7M |
| SG&A Expense | 22.9M | 11.0M | 11.9M | 11.7M | 14.5M |
| General & Admin Expense | 22.9M | 11.0M | 11.6M | 11.4M | 13.9M |
| Selling & Marketing Expense | — | — | 309.0K | 316.0K | 530.0K |
| Other Expenses | 2.0M | 1.6M | 283.0K | (49.5M) | (2.7M) |
| Total Operating Expenses | 120.4M | 56.2M | 64.2M | 18.3M | 63.4M |
| Cost and Expenses | 120.4M | 56.2M | 64.2M | 74.3M | 115.1M |
| Operating Income (EBIT) | (105.0M) | (53.4M) | (51.6M) | (12.7M) | (57.4M) |
| Non-Operating | |||||
| Interest Income | 10.3M | 1.3M | 2.4M | 3.2M | 546.0K |
| Interest Expense | 3.5M | 440.0K | 566.0K | 640.0K | 288.0K |
| Net Interest Income | 6.8M | 878.0K | 1.9M | 2.5M | 258.0K |
| Other Non-Op Income/Expense | 6.4M | 4.2M | 2.1M | 5.1M | (547.0K) |
| Non-Operating Income (excl Interest) | (2.7M) | (4.7M) | (2.7M) | (5.7M) | 259.0K |
| EBT (Pre-Tax Income) | (98.6M) | (49.2M) | (49.5M) | (7.6M) | (58.0M) |
| Income Tax Expense | (3.0M) | — | — | — | — |
| Bottom Line | |||||
| Net Income | (98.4M) | (49.2M) | (49.5M) | (7.6M) | (58.1M) |
| Earnings from Cont. Ops | (98.4M) | (49.2M) | (49.5M) | (7.6M) | (58.0M) |
| Earnings from Discont. Ops | — | — | — | — | (131.0K) |
| Bottom Line Net Income | (98.6M) | (49.2M) | (49.5M) | (7.6M) | (58.1M) |
| Per Share | |||||
| Basic EPS | ($1.16) | ($0.53) | ($0.61) | ($0.09) | ($0.73) |
| Diluted EPS | ($1.16) | ($0.53) | ($0.61) | ($0.09) | ($0.73) |
| Revenue Per Share | $0.17 | $0.03 | $0.16 | $0.62 | $0.72 |
| Shares | |||||
| Basic Shares Outstanding | 91.4M | 89.4M | 81.1M | 84.1M | 79.6M |
| Diluted Shares Outstanding | 91.4M | 89.4M | 81.1M | 84.1M | 79.6M |
| Profitability Metrics | |||||
| EBITDA | (102.7M) | (43.6M) | (46.9M) | (1.8M) | (12.3M) |
| D&A | 3.0M | 5.1M | 2.0M | 5.1M | 45.4M |
| EBIT | (105.7M) | (48.7M) | (48.9M) | (6.9M) | (57.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025